Project Grant R01HL169793
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$758K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $3,727,090 to Geneventiv Therapeutics, Inc. to develop a universal gene therapy for hemophilia A or B, with or without inhibitors. The goal is to create an adeno-associated virus (AAV) vector encoding human Factor VA that can bypass the need for Factor VIII or Factor IX and restore normal clotting without the risk of thrombosis, even...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research focused on developing a novel treatment for familial hypercholesterolemia (FH). The project aims to deliver CRISPR-Cas9 gene editing components into hepatocytes (liver cells) using non-viral delivery methods, then transplant the engineered cells to replace diseased cells and lower cholesterol and triglyceride levels. Key activities include:
Comparing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $486,291 to Rutgers, The State University of New Jersey, Camden Division to develop nucleic acid nanoparticle (NANP) technology for efficiently delivering the CRISPR/Cas9 gene editing system into hematopoietic stem cells (HSCs). The goal is to enhance the precision and efficiency of genome editing in HSCs to advance the treatment of...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of an in vivo gene therapy for sickle cell disease using a novel lentiviral delivery platform. The $300,000 award to Gigamune, Inc. aims to assess the efficiency and specificity of hematopoietic stem cell-tropic lentiviral vectors for delivering CRISPR/Cas9 machinery to knockout the BCL11A enhancer or express...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $704,635 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Florida to develop optimized adeno-associated virus (AAV) vector constructs for gene therapy of hemophilia.
The grant aims to combine capsid and genome modifications to AAV3 vectors to enhance their transduction efficiency and transgene expression in human hepatocytes, with the goal of achieving improved therapeutic efficacy at...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $889,998.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop an alpha-retroviral vector platform for in vivo and ex vivo delivery of gene therapy payloads to hematopoietic stem cells. The long-term goal is to enable simpler, more economical, and widespread application of gene therapies to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $270,000 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Toronto to develop a nonviral base editing system for treating cystic fibrosis (CF) with nonsense mutations. The project aims to: 1) chemically refine adenine base editors (ABEs) to achieve optimal on-target gene-editing; 2) develop and fine-tune lipid nanoparticle (LNP) formulations for pulmonary delivery; and 3) conduct in vivo validation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services is focused on developing chemically inducible split base editors for precise and controllable in vivo genome editing. The $667,704 award, with a project period from February 1, 2025 to November 30, 2028, supports research conducted by the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,845,871 to the University of Kansas Medical Center Research Institute (KUMCRI) to develop novel gene editing therapies for cystic fibrosis (CF). The key objectives are to:
Use a CRISPR-based "homology-independent targeted integration" (HITI) approach to permanently correct the CFTR gene defect in airway epithelial cells, including...
The U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute (NHLBI) awarded a $685,621 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Rio Grande Valley (UTRGV) to conduct research on genetic and environmental factors influencing the development of factor VIII inhibitors in hemophilia A patients of Mexican ancestry. The key objectives are to:
Enroll and characterize a cohort of 200 severe hemophilia A patients of...